McKenna's Drug Handbook for Nursing & Midwifery, 7e

Diagnostic preparations     1303

Available form Prefilled syringe: 181.43mg/mL (0.25mmol/ mL) in 10 mL Indications & dosages ➤ EnhancementofMRIoffocal liver lesions— Adults: 0.1mL/kgbodyweight(25micromol/ kg) by IV bolus or infusion. Action Paramagnetic contrast agent used for imag­ ing of intracranial and spinal lesions in presence of abnormal blood–brain barrier or abnormal vascularity, as well as whole- Adverse reactions CNS: akathisia, dizziness, dysgeusia, head­ ache, paraesthesia, parosmia, restlessness, tremor, vertigo. CV: bundle branch block, flushing, hyper­ tension, palpitations, tachycardia, QT prolongation . GI: dry mouth, nausea, oral discomfort, salivary hypersecretion, vomiting. GU: acute kidney injury . Musculoskeletal: back pain, chest pain, nephrogenic systemic fibrosis . Respiratory: dyspnoea , respiratorydistress . Skin: hyperhidrosis, pruritus, rash, urticaria. Other: anaphylactic reaction , angio- oedema , chills, fatigue, hypersensitivity, injection site pain, malaise. Interactions Drug-drug. Rifampicin: Blocked hepatic uptake of gadoxetic acid and reduced hepatic contrast effect. Contraindications Contraindicated in individuals with known hypersensitivity to the preparation. body imaging. Route Onset Peak Duration IV Immediate Unknown Unknown

Respiratory: apnoea , bronchospasm , cough, dyspnoea, laryngeal oedema , rhinitis, wheezing. Skin: erythema, pruritus, sweating, urticaria. Other: anaphylactic reaction , angio- oedema , asthenia, fatigue, hypersensitivity, injection site pain, malaise. Interactions None reported. Contraindications Contraindicated in individuals with known hypersensitivity to the preparation or other gadolinium-based contrast media and in children under 6 months of age. care considerations • Increased risk of nephrogenic systemic fibrosis in individuals with acute or chronic renal failure or acute renal insufficiency, or during the perioperative period in liver transplantation. Renal function should be assessed in all individuals prior to the procedure. • For individuals on chronic haemodialysis, initiate haemodialysis promptly following administration of gadoteridol to increase elimination. • Closelymonitor individualfordevelopment of anaphylactic reaction. Ensure emergency management equipment is available and in correct working order. • Monitor vital signs closely following procedure. Patient teaching • Advise person to report any adverse effects.

gadoxetic acid Primovist Pregnancy risk category B3 Use in sport: Permitted